Mouse Anti-F13A1 Recombinant Antibody (CB49A) (CBMAB-CA049LY)

Name: Mouse Anti-F13A1 Recombinant Antibody (CB49A)
SKU: CBMAB-CA049LY
Rating: 5 (1 reviews)

See all F13A1 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CB49A

Application

WB, IHC-P, FC

Immunogen

Full length human recombinant protein of human F13A1.

Host Species

Mouse

Specificity

Human

Antibody Isotype

IgG1

Clonality

Monoclonal Antibody

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
WB	1:2,000
IHC-P	1:150
FC	1:100

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, glycerol, BSA

Preservative

Sodium azide

Concentration

Batch dependent

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

Coagulation Factor XIII A Chain

Introduction

This gene encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion. [provided by RefSeq, Jul 2008]

Entrez Gene ID

2162

UniProt ID

P00488

Alternative Names

Coagulation Factor XIII A Chain; Protein-Glutamine Gamma-Glutamyltransferase A Chain; Coagulation Factor XIII, A1 Polypeptide; Coagulation Factor XIIIa; Transglutaminase A Chain; EC 2.3.2.13; F13A; BA525O21.1 (Coagulation Factor XIII, A1 Polypeptide);

Research Area

Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin.

Biological Process

Blood coagulation Source: ProtInc
Blood coagulation, fibrin clot formation Source: UniProtKB
Peptide cross-linking Source: UniProtKB

Cellular Location

Secreted; Cytoplasm. Secreted into the blood plasma. Cytoplasmic in most tissues, but also secreted in the blood plasma.

Involvement in disease

Factor XIII subunit A deficiency (FA13AD):
An autosomal recessive hematologic disorder characterized by a life-long bleeding tendency, impaired wound healing and spontaneous abortion in affected women.

PTM

The activation peptide is released by thrombin.

Xie, H., Wang, M., Jin, Y., Li, X., Jiang, S., & Yang, L. (2022). A novel F13A1 gene mutation (Arg208Pro) in a Chinese patient with factor XIII deficiency. Blood Coagulation & Fibrinolysis, 33(6), 337-341.

Katsaras, G. N., Gialamprinou, D., Chatziioannidis, I., Karagianni, P., & Mitsiakos, G. (2022). Coagulation factor XIII deficiency–Report of a newborn F13A1 Val34Leu polymorphism carrier. Journal of Pediatric and Neonatal Individualized Medicine (JPNIM), 11(2), e110238-e110238.

Kaartinen, M. T., Arora, M., Heinonen, S., Hang, A., Barry, A., Lundbom, J., ... & Pietiläinen, K. H. (2021). F13A1 transglutaminase expression in human adipose tissue increases in acquired excess weight and associates with inflammatory status of adipocytes. International Journal of Obesity, 45(3), 577-587.

Ercan, H., Mauracher, L. M., Grilz, E., Hell, L., Hellinger, R., Schmid, J. A., ... & Zellner, M. (2021). Alterations of the platelet proteome in lung cancer: Accelerated F13A1 and ER processing as new actors in hypercoagulability. Cancers, 13(9), 2260.

Kaartinen, M. T., Arora, M., Heinonen, S., Rissanen, A., Kaprio, J., & Pietiläinen, K. H. (2020). Transglutaminases and Obesity in Humans: Association of F13A1 to Adipocyte Hypertrophy and Adipose Tissue Immune Response. International journal of molecular sciences, 21(21), 8289.

Songdej, N., Del Carpio-cano, F., Mao, G., Wurtzel, J., Goldfinger, L., Lambert, M. P., & Rao, A. K. (2020). Transcription factor RUNX1 regulates factor FXIIIA subunit (F13A1) expression in megakaryocytic cells and platelet F13A1 expression is downregulated in RUNX1 haplodeficiency. Blood, 136, 25-26.

Ma, S., Chen, C., Liang, Q., Wu, X., Wang, X., Wu, W., ... & Ding, Q. (2019). Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement. Orphanet journal of rare diseases, 14(1), 1-10.

Ansani, L., Marchesini, J., Pestelli, G., Luisi, G. A., Scillitani, G., Longo, G., ... & Gemmati, D. (2018). F13A1 gene variant (V34L) and residual circulating FXIIIA levels predict short-and long-term mortality in acute myocardial infarction after coronary angioplasty. International journal of molecular sciences, 19(9), 2766.

Gemmati, D., Occhionorelli, S., Tisato, V., Vigliano, M., Longo, G., Gonelli, A., ... & Zamboni, P. (2018). Inherited genetic predispositions in F13A1 and F13B genes predict abdominal adhesion formation: Identification of gender prognostic indicators. Scientific reports, 8(1), 1-13.

Peltier, J., Roperch, J. P., Audebert, S., Borg, J. P., & Camoin, L. (2018). Activation peptide of the coagulation factor XIII (AP-F13A1) as a new biomarker for the screening of colorectal cancer. Clinical proteomics, 15(1), 1-11.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-F13A1 Recombinant Antibody (CB49A)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Antibody Pairs

F13A1 Matched Antibody Pair (395) (CAT#: APMAB-395LY)

Related Products

Rabbit Anti-F13A1 Recombinant Antibody (EP3372) (CAT#: CBMAB-R0025-FY)

Mouse Anti-F13A1 Recombinant Antibody (CBXF-3769) (CAT#: CBMAB-F2382-CQ)

Mouse Anti-F13A1 Recombinant Antibody (CBXF-3551) (CAT#: CBMAB-F2092-CQ)

F13A1 Matched Antibody Pair (395) (CAT#: APMAB-395LY)

Mouse Anti-F13A1 Recombinant Antibody (M1) (CAT#: V2LY-0825-LY1074)

Mouse Anti-F13A1 Recombinant Antibody (CBXF-2287) (CAT#: V2LY-0825-LY1070)

Rabbit Anti-F13A1 Recombinant Antibody (CBXF-1073) (CAT#: V2LY-0825-LY1065)

Mouse Anti-F13A1 Recombinant Antibody (CBXF-0147) (CAT#: V2LY-0825-LY1067)

Mouse Anti-F13A1 Recombinant Antibody (F1655) (CAT#: V2LY-0825-LY1068)

Mouse Anti-F13A1 Recombinant Antibody (F2148) (CAT#: V2LY-0825-LY1072)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry